These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 33506447)
1. Graves' Orbitopathy: Current Concepts for Medical Treatment. Oeverhaus M; Stöhr M; Möller L; Führer D; Eckstein A Klin Monbl Augenheilkd; 2021 Jan; 238(1):24-32. PubMed ID: 33506447 [TBL] [Abstract][Full Text] [Related]
2. [Graves' orbitopathy: Current concepts for medical treatment]. Oeverhaus M; Stöhr M; Möller L; Führer D; Eckstein A Laryngorhinootologie; 2023 Mar; 102(3):177-185. PubMed ID: 36858060 [TBL] [Abstract][Full Text] [Related]
4. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Bartalena L; Kahaly GJ; Baldeschi L; Dayan CM; Eckstein A; Marcocci C; Marinò M; Vaidya B; Wiersinga WM; Eur J Endocrinol; 2021 Aug; 185(4):G43-G67. PubMed ID: 34297684 [TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for Graves' orbitopathy in patients who underwent anti-inflammatory and immunosuppressive treatment during medical treatment for Graves' disease: investigation of 1,553 cases with newly diagnosed Graves' disease and proposal of a predictive score. Watanabe N; Yoshimura Noh J; Kozaki A; Yoshimura R; Yoshihara A; Suzuki N; Matsumoto M; Fukushita M; Kinoshita A; Aida A; Imai H; Hiruma S; Inoue T; Inoue K; Sugino K; Ito K Endocr J; 2023 Nov; 70(11):1087-1096. PubMed ID: 37743517 [TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy. Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519 [TBL] [Abstract][Full Text] [Related]
15. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment. Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204 [No Abstract] [Full Text] [Related]
16. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469 [TBL] [Abstract][Full Text] [Related]
17. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study. Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054 [TBL] [Abstract][Full Text] [Related]